Latest News and Press Releases

Tyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial Participants

aTyr Pharma to present posters on the importance of Neuropilin-2 in immune regulation at the Keystone Symposia on Myeloid Cell Diversity.

aTyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as Advisor for efzofitimod program in interstitial lung disease (ILD).

aTyr Pharma announces that it will present at two investor conferences in November 2023.

Post-hoc analysis from Phase 1b/2a study in pulmonary sarcoidosis presented at the European Respiratory Society (ERS) International Congress 2023. 7.7% of patients in the 3.0 and 5.0 mg/kg...

SAN DIEGO, Aug. 24, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary...

Proof-of-Concept study in SSc-ILD expected to begin in 2023. Efzofitimod has been granted U.S. FDA orphan drug designation for SSc and Fast Track designation for SSc-ILD. SAN DIEGO, March 01, 2023 ...

First therapy in sarcoidosis to reduce steroid burden while demonstrating improvements in key physiologic and quality of life measures. Global pivotal Phase 3 EFZO-FIT™ study currently enrolling. ...

SAN DIEGO, Oct. 11, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or “the Company”), a biotherapeutics company engaged in the discovery and development of first-in-class medicines...

Multiple centers in the U.S. are open for enrollment for double-blind, randomized, placebo-controlled study. Primary endpoint will evaluate steroid-sparing effect of efzofitimod compared to placebo. ...